Literature DB >> 15816865

Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.

Cheng Wang1, Jeanne M M Tan, Michelle W L Ho, Norazean Zaiden, Siew Heng Wong, Constance L C Chew, Pei Woon Eng, Tit Meng Lim, Ted M Dawson, Kah Leong Lim.   

Abstract

Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity. However, a number of recent studies, including ours, have indicated that many disease-linked point mutants of parkin retain substantial catalytic activity. To understand how the plethora of mutations on parkin contribute to its dysfunction, we have conducted a systematic analysis of a significant number of parkin point mutants (22 in total), which represent the majority of parkin missense/nonsense mutations reported to date. We found that more than half of these mutations, including many located outside of the parkin RING fingers, produce alteration in the solubility of parkin which influences its detergent extraction property. This mutation-mediated alteration in parkin solubility is also associated with its propensity to form intracellular, aggresome-like, protein aggregates. However, they do not represent sites where parkin substrates become sequestered. As protein aggregation sequesters the functional forms away from their normal sites of action, our results suggest that alterations in parkin solubility and intracellular localization may underlie the molecular basis of the loss of function caused by several of its mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816865     DOI: 10.1111/j.1471-4159.2005.03023.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  51 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.

Authors:  Sher Hayat Khan; Deming Zhao; Syed Zahid Ali Shah; Mohammad Farooque Hassan; Ting Zhu; Zhiqi Song; Xiangmei Zhou; Lifeng Yang
Journal:  Cell Mol Neurobiol       Date:  2016-07-18       Impact factor: 5.046

Review 3.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

4.  Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.

Authors:  Cheng Wang; Ruifeng Lu; Xuezhi Ouyang; Michelle W L Ho; William Chia; Fengwei Yu; Kah-Leong Lim
Journal:  J Neurosci       Date:  2007-08-08       Impact factor: 6.167

Review 5.  The role of parkin in familial and sporadic Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

6.  PINK1 and Parkin are genetic modifiers for FUS-induced neurodegeneration.

Authors:  Yanbo Chen; Jianwen Deng; Peng Wang; Mengxue Yang; Xiaoping Chen; Li Zhu; Jianghong Liu; Bingwei Lu; Yan Shen; Kazuo Fushimi; Qi Xu; Jane Y Wu
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 7.  Mitochondrial dynamics and Parkinson's disease: focus on parkin.

Authors:  Kah-Leong Lim; Xiao-Hui Ng; Lim Gui-Yin Grace; Tso-Pang Yao
Journal:  Antioxid Redox Signal       Date:  2011-07-22       Impact factor: 8.401

8.  Identification and characterization of a novel endogenous murine parkin mutation.

Authors:  Chenere P Ramsey; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

9.  Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy.

Authors:  Joo-Yong Lee; Yoshito Nagano; J Paul Taylor; Kah Leong Lim; Tso-Pang Yao
Journal:  J Cell Biol       Date:  2010-05-10       Impact factor: 10.539

10.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.